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Light-chain amyloidosis (AL) is a degenerative disease characterized
by the extracellular aggregation of a destabilized amyloidogenic Ig
light chain (LC) secreted from a clonally expanded plasma cell.
Current treatments for AL revolve around ablating the cancer
plasma cell population using chemotherapy regimens. Unfortu-
nately, this approach is limited to the ∼70% of patients who do
not exhibit significant organ proteotoxicity and can tolerate chemo-
therapy. Thus, identifying new therapeutic strategies to alleviate LC
organ proteotoxicity should allow AL patients with significant car-
diac and/or renal involvement to subsequently tolerate established
chemotherapy treatments. Using a small-molecule screening ap-
proach, the unfolded protein response (UPR) was identified as a cel-
lular signaling pathway whose activation selectively attenuates
secretion of amyloidogenic LC, while not affecting secretion of
a nonamyloidogenic LC. Activation of the UPR-associated transcrip-
tion factors XBP1s and/or ATF6 in the absence of stress recapitulates
the selective decrease in amyloidogenic LC secretion by remodeling
the endoplasmic reticulum proteostasis network. Stress-indepen-
dent activation of XBP1s, or especially ATF6, also attenuates extra-
cellular aggregation of amyloidogenic LC into soluble aggregates.
Collectively, our results show that stress-independent activation of
these adaptive UPR transcription factors offers a therapeutic strat-
egy to reduce proteotoxicity associated with LC aggregation.
ER proteostasis | amyloid
Light-chain amyloidosis (AL) afflicts 8–10 people per millionper year, making it the most prominent systemic amyloid dis-
ease (1). AL is a gain-of-toxic function disease driven by a clonally
expanded plasma cell that secretes amyloidogenic Ig light chains
(LCs). These amyloidogenic LCs undergo extracellular misfolding
and aggregation into proteotoxic soluble oligomers and amyloid
fibrils that interact with distal tissues such as the kidney, heart, and
gastrointestinal tract, leading to organ dysfunction and ultimately
death by unknown proteotoxicity mechanism(s) (2).
The majority of AL patients must combat both a cancer (i.e.,
the clonally expanded plasma cell) and LC aggregation-associated
proteotoxicity. The standard treatment for AL patients is che-
motherapy (often combined with stem cell transplant) to eliminate
the cancerous plasma cell population (3, 4). The proteasome in-
hibitor bortezomib, which takes advantage of the stress sensitivity
of aggressively proliferating plasma cells, has transformed che-
motherapy effectiveness (5–7). Regardless, ∼30% of AL patients
with substantial cardiac or renal LC proteotoxicity are too ill
at diagnosis to tolerate chemotherapeutics (8–10). Thus, new
strategies to reduce LC organ proteotoxicity must be developed
to allow more AL patients to take advantage of chemotherapy.
LC aggregation requires conformational changes and a sufficient
concentration of misfolded LC in plasma, which determine the rate
and extent of its concentration-dependent aggregation. Over 500
distinct LC sequences, primarily of the lambda (λ) isotype (11),
have been identified in AL amyloid deposits, reflecting the signif-
icant protein heterogeneity associated with AL proteotoxicity (12).
Amyloidogenic LCs generally contain an energetically destabilized
variable domain that facilitates LC aggregation (2).
The amyloidogenic LC plasma concentration is determined by
the extent of LC secretion from plasma cells and the rate of LC
turnover in the serum. Secretion efficiency is largely dictated by
the balance between folding vs. degradation, often referred to as
“quality control,” in the endoplasmic reticulum (ER) (13). ER
quality control is determined by the activity of the ER protein
homeostasis (proteostasis) network comprising the protein fold-
ing, secretion, and degradation pathways (14–19). These pathways
primarily function to prevent the secretion of destabilized, mis-
folding-prone proteins into the extracellular space (14–19).
Plasma cells have an evolutionarily enhanced ER and secretory
pathway, enabling the proper folding and secretion of >1,000 IgGs
per second (20, 21). Plasma cells normally secrete LC as IgGs [as-
semblies of two LCs and two heavy chains (HCs)], or as free LCs.
However, in AL patients, LCs are predominantly secreted in-
dependent of HCs, sometimes as monomers, but generally as disul-
fide-linked homodimers called Bence−Jones proteins—the common
precursor for LC aggregation (22, 23). Furthermore, LC ER quality
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control is compromised in AL, allowing the efficient secretion of
destabilized, amyloidogenic LC sequences that can aggregate extra-
cellularly into proteotoxic soluble oligomers and amyloid fibrils.
Herein, we sought to identify signaling pathways that can be
activated to reduce the secretion of destabilized, amyloidogenic
LCs, thus reducing the extracellular LC concentration available for
pathologic, concentration-dependent aggregation. Using a small-
molecule screening approach, we identified that unfolded protein
response (UPR) (24, 25) activation selectively reduces the secre-
tion of a destabilized, amyloidogenic LC but not a more stable,
nonamyloidogenic LC sequence. The UPR transcriptionally up-
regulates ER quality control in response to ER stress, primarily
through the transcription factors XBP1s and/or ATF6, comprising
the adaptive UPR (25). Here, we show that stress-independent
activation of XBP1s and especially ATF6 is sufficient to reduce
amyloidogenic LC secretion and attenuate LC aggregation. Col-
lectively, our results demonstrate that enhancing ER quality con-
trol via adaptive UPR activation represents a therapeutic strategy
to ameliorate LC aggregation-associated proteotoxicity.
Results
Screening Reveals That UPR Activation Reduces Amyloidogenic LC
Secretion. We developed a secretion reporter for LC by fusing
the well-characterized AL-causing Vλ6 LC containing both con-
stant and variable LC domains (named ALLC) (26) to an en-
hanced Gaussia princeps luciferase (GLuc) reporter, ALLC-GLuc
(Fig. 1A) (27, 28). We used a similar GLuc fusion approach to
quantify secretion of other proteins in a cell-based high-through-
put screening (HTS) format (29). The secretion of ALLC-GLuc
from HEK293-TRex cells was observable by immunoblotting and
luminescence (Fig. S1 A and B). ALLC secretion decreased upon
inhibition of protein biosynthesis using cycloheximide (CHX) or
after inhibition of global protein secretion using brefeldin A (Fig.
S1C), as did the secretion of GLuc, used as a control. ALLC-GLuc
or GLuc was then stably incorporated into retinal pigment epi-
thelium (ARPE-19) cells, as we previously optimized these pro-
fessional secretory cells for HTS of GLuc fusion proteins such as
ALLC-GLuc (29). The ALLC-GLuc secretion assay was minia-
turized to a 384-well plate format, affording an HTS z-score (30)
of 0.65 using cycloxheximide as a control.
To identify biologic pathways that selectively reduce secretion
of ALLC-GLuc, we screened the Library of Pharmacologically
Active Compounds (LOPAC, Sigma Aldrich) in ARPE-19 cells
secreting ALLC-GLuc or GLuc. The LOPAC was chosen be-
cause it is moderately sized (1,280 compounds), consists of
compounds from major drug categories, and the biological tar-
gets for many small molecule components are known. We
identified 15 molecules that significantly reduced ALLC-GLuc
secretion (>25% reduction vs. vehicle control, 24-h treatment),
while not affecting GLuc secretion (Fig. 1B, section shaded
blue). Molecules that disrupted both ALLC-GLuc and GLuc
secretion were not pursued further, as these likely reduce protein
synthesis and/or disrupt global cell secretion (e.g., CHX and
brefeldin A in Fig. S1C). Interestingly, the UPR activators
thapsigargin (Tg), an inhibitor of sarco/endoplasmic reticulum
Ca2+-ATPase (31), and ellipticene (32) selectively reduced ALLC
secretion relative to GLuc (Fig. 1B), suggesting that activation of
the UPR could selectively influence LC secretion. The inability of
a 24-h treatment with Tg to influence GLuc secretion is consis-
tent with previous results (27).
To further examine the relationship between UPR activation
and the reduction in ALLC-GLuc secretion, we performed an
additional screen using HEK293T-Rex cells stably expressing
firefly luciferase under the control of the ER stress-responsive
element (ERSE) promoter (ERSE-FLuc, Fig. 1A) (33). We
found that 7 out of 15 molecules that selectively reduce ALLC-
GLuc secretion by >25% also activated the ERSE-FLuc reporter
>1.5 fold (Fig. 1C, blue), indicating that molecules that reduce
ALLC-GLuc secretion are enriched for UPR activators.
Thapsigargin Selectively Reduces ALLC Secretion. To further un-
derstand the effect of ER stress-associated UPR activation on
LC secretion, we used [35S]-metabolic labeling to measure the
secretion of amyloidogenic ALLC fused to an N-terminal FLAG
tag (FTALLC, Fig. 2A). We preincubated cells in the absence or
presence of Tg for 15 h to promote UPR-dependent remodeling
of the ER proteostasis network before [35S]-metabolic label-
ing (Fig. 2A). FTALLC was immunopurified from media and
cell lysates at specific timepoints during a 4-h chase in non-
radioactive media. These experiments show that Tg pretreatment
reduces FTALLC secretion by >40% (Fig. 2B). Importantly,
because our Tg treatments do not drastically influence cell via-
bility (Fig. S2 A and B), the Tg-dependent reduction in ALLC
secretion cannot be attributed to cell toxicity. Furthermore the
Tg-dependent reduction in ALLC secretion is also observed in
cells treated with the protein kinase R-like ER kinase (PERK)
inhibitor GSK2606414 (34), demonstrating that the reduced se-
cretion does not result from PERK-dependent translational at-
tenuation (Fig. S2C).
No accumulation of FTALLC was observed in cell pellets fol-
lowing ER stress caused by Tg treatment (Fig. 2C), indicating that
ALLC does not accumulate as intracellular aggregates. Re-
duced FTALLC secretion was associated with a decrease in total
[35S]-labeled FTALLC (media + lysate) (Fig. 2D), suggesting that
Tg-associated ER stress increases FTALLC degradation. Similar
results were obtained with an untagged ALLC, confirming that
the FLAG tag does not significantly influence ALLC secretion
and/or degradation (Fig. S2 D and E). This Tg-dependent loss in
total FTALLC cannot be reversed using proteasome inhibitors
(bortezomib or MG132) or the p97 inhibitor eeyarestatin I
[a potent inhibitor of ER-associated degradation (ERAD) (35)],
Fig. 1. ALLC-GLuc reporter screening identifies UPR modulators able to
reduce secretion of amyloidogenic LC. (A) Schematic of GLuc, ALLC-GLuc,
and ERSE-FLuc reporter constructs used in stable ARPE19 or HEK293T-Rex cell
lines. ERSE-FLuc transcriptional reporter includes the ERSE-containing por-
tion of the BiP promoter upstream of the firefly luciferase (FLuc) gene. SS,
signal sequence. (B) Plot of LOPAC screening data comparing ALLC-GLuc
secretion vs. GLuc secretion. ARPE-19 cells stably expressing ALLC-GLuc or
GLuc alone were treated with compound (10 μM) for 24 h. Shaded blue
section indicates compounds that reduce ALLC-GLuc secretion (>25%) and
do not affect GLuc secretion (<±15% from DMSO control). (C) Plot of LOPAC
screening results comparing ALLC-GLuc secretion (ARPE-19 cells, 24-h treat-
ment) vs. UPR activation (ERSE-FLuc expressing HEK293T-Rex cells, 18-h
treatment). Compounds falling below the horizontal line reduce ALLC-GLuc
secretion by 25%. Compounds falling to the right of the vertical line increase
ERSE-FLuc expression >1.5-fold relative to DMSO control. Compounds
depicted in red are known activators of the UPR.
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indicating that FTALLC is degraded following ER stress, at least
in part through an ERAD-independent mechanism (Fig. 2E)
(36). In contrast, the autophagy inhibitor chloroquine stabi-
lized ALLC against Tg-induced degradation, indicating that
Tg increases the autophagic degradation of ALLC (Fig. 2E).
Destabilized proteins are sensitive to UPR-dependent remod-
eling of the ER proteostasis network, whereas stable variants are
generally less sensitive to this remodeling (37). Thus, we evaluated
whether Tg-dependent reductions in LC secretion are also ob-
served for a nonamyloidogenic, full-length Vλ6 LC, FTJTO (38).
Tg pretreatment did not reduce the secretion of [35S]-labeled,
nonamyloidogenic FTJTO (Fig. 2F), indicating that Tg-dependent
UPR activation selectively reduces the secretion of an amyloido-
genic, but not a nonamyloidogenic LC.
LC amyloidogenicity is highly correlated with LC stability (38,
39). Thus, we compared the in vitro relative stability of recombi-
nant ALLC and JTO. Circular dichroism and tryptophan fluo-
rescence measurements confirmed that the recombinant proteins
have a folded, native β-sheet-rich Ig structure (Fig. S3 A and B).
The relative stability of the ALLC and JTO LCs were compared
by urea denaturation and monitored by tryptophan fluorescence
(Fig. S3C). Although the ALLC unfolding transition is not com-
pletely reversible (Fig. S3A, black curve), the urea midpoint values
for the denaturation curves (ALLC 1.8 M, JTO 2.6 M) indicate
that ALLC is less stable than JTO (Fig. S3C). This suggests that
the selective decrease in ALLC secretion afforded by Tg could be
attributed to the inherent instability of the ALLC protein.
XBP1s and/or ATF6 Activation Reduces the Secretion of Destabilized
ALLC. Previous work has indicated that remodeling of ER pro-
teostasis pathways selectively influences the secretion of desta-
bilized protein variants relative to more stable protein variants
(13, 40, 41). Thus, Tg-dependent UPR activation could selec-
tively decrease the secretion of destabilized ALLC through the
transcriptional remodeling of the ER proteostasis network. To
differentiate between the potential effects of Tg-induced ER stress
and UPR-dependent remodeling of ER proteostasis pathways on
ALLC secretion, we used a HEK293T-Rex-derived cell line that
expresses both a ligand-regulatable ATF6 transcription factor
[DHFR-ATF6; activated by the addition of the small molecule
pharmacologic chaperone trimethoprim (TMP)] and a doxy-
cycline (Dox)-inducible XBP1s transcription factor (cells referred to
as HEK293DAX) (40). In these cells, the ATF6 or XBP1s tran-
scriptional programs can be orthogonally controlled in the ab-
sence of ER stress, which enables analysis of the functional
consequences of arm-selective UPR activation independently,
or in combination (Fig. S4A) (40).
We treated HEK293DAX cells expressing FTALLC with Dox,
TMP, or Tg and quantified the FTALLC levels in conditioned
media by ELISA (Fig. 3A). Stress-independent activation of
XBP1s or ATF6 reduced extracellular FTALLC levels to 68% and
48% of vehicle levels, respectively. Tg treatment lowered FTALLC
levels to 34%. Reduced FTALLC secretion induced by XBP1s
or ATF6 activation was dependent on transcription factor activity,
as no reduction in FTALLC secretion was observed in TMP- or
Dox-treated HEK293DYG cells—a control cell line stably expressing
DHFR-YFP and Dox-inducible GFP (Fig. S4B) (40).
To probe the basis for the XBP1s- or ATF6-mediated reduction in
ALLC secretion, we used [35S]-metabolic labeling (Fig. 3 B−E).
XBP1s, ATF6, or combinatorial activation lowered the relative se-
creted fraction of labeled ALLC by ∼40% following a 4-h chase
(Fig. 3 B and C). In contrast, stress-independent activation of
XBP1s and/or ATF6 did not affect the secretion of the non-
amyloidogenic FTJTO (Fig. S4C). Notably, XBP1s- and ATF6-
dependent reductions in ALLC secretion proceed through distinct
mechanisms. XBP1s activation resulted in a 25% decrease in total
[35S]-labeled FTALLC (Fig. 3D), as observed for Tg-treatment (Fig.
2D). This XBP1s-dependent decrease in total soluble ALLC was not
Fig. 2. Thapsigargin selectively reduces the secretion of amyloidogenic LC and induces its degradation. (A) Schematic of the FTALLC construct used in pulse-
chase experiments and the metabolic labeling protocol used. [35S]-labeled FTALLC was immunopurified from media and lysates collected from transfected
HEK293T-Rex cells following a 15-h treatment with thapsigargin (Tg, 500 nM). (B) Representative autoradiogram and quantification of [35S]-labeled FTALLC in
pulse-chase experiment described in A. Fraction secreted was calculated as described in Materials and Methods (18) (n ≥ 3). (C) Immunoblots measuring
soluble and insoluble (pellet) levels of FTALLC after 15-h pretreatment with Tg. (D) Graph depicting total [35S]-labeled FTALLC (combined media and lysate
protein levels as in B) remaining at 4 h in HEK293T-Rex cells following a 15-h pretreatment with 500 nM Tg (n ≥ 3). The fraction remaining was calculated as
described in Materials and Methods (18). (E) Graph depicting the fraction recovery of total [35S]- labeled FTALLC at 4 h in HEK293T-Rex cells incubated in the
presence of thapsigargin (Tg; 500 nM, 15 h) and the proteasome inhibitors bortezomib (Bz; 20 μM) or MG132 (MG; 20 μM), the ERAD inhibitor eeyarestatin
I (EerI; 20 μM), or the autophagy inhibitor chloroquine (Cq; 100 μM). Inhibitors were incubated for 4 h before [35S] metabolic labeling and included
throughout the labeling protocol shown in A. Fraction remaining was calculated as in D (n ≥ 2). (F) Representative autoradiogram and quantification of
[35S]-labeled FTJTO immunopurified frommedia and lysates collected from transfected HEK293T-Rex cells following the same protocol and quantification as in
A and B (n ≥ 3). *P < 0.05; ***P < 0.005. All error bars represent the SEM from biological replicates.
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a result of intracellular accumulation of FTALLC in the cell pellet
(Fig. S4D), implying the loss of FTALLC is due to degradation and not
intracellular aggregation. ATF6 activation, in contrast, did not de-
crease total ALLC recovery in our [35S] metabolic labeling experi-
ments (Fig. 3D) but instead resulted in an increase in intracellular
[35S]-labeled FTALLC (Fig. 3E). Coactivation of XBP1s and ATF6
decreases FTALLC recovery to that observed for XBP1s activation.
Similar results were observed with untagged ALLC (Fig. S5).
Altered processing of ALLC in the ER after XBP1s and/or
ATF6 activation likely reflects distinct interactions between
ALLC and ER proteostasis network components differentially
induced by these transcriptional programs. We used an in situ
cross-linking and immunopurification approach to sensitively
measure the intracellular associations between ALLC and ER
chaperones such as BiP (GRP78) and GRP94 (Fig. S6A)—two
ER chaperones known to interact with LC (42, 43). As predicted,
ATF6 activation, but not XBP1s activation, resulted in a signifi-
cant increase in the association between ALLC and the ATF6-
regulated ER chaperones BiP and GRP94 (Fig. 3 F and G),
reflecting the increased levels of these two ER chaperones
afforded by ATF6 activation (40). The increased association
between ALLC and these ER proteostasis factors provides a
mechanism to explain the ATF6-induced intracellular reten-
tion of destabilized, aggregation-prone ALLC in the ER lumen.
ATF6 activation also increased interactions between FTJTO
and BiP and GRP94 (Fig. S6B), albeit to a lesser extent than
that observed for ALLC (Fig. 3 F and G).
XBP1s and/or ATF6 Decreases Extracellular Aggregation of Secreted
ALLC. Lowering the secretion of an amyloidogenic LC should di-
rectly ameliorate AL organ proteotoxicity by reducing the extra-
cellular concentration and therefore the extracellular aggregation
of amyloidogenic LCs. To scrutinize this hypothesis, we examined
the concentration-dependent aggregation of recombinant ALLC
by monitoring turbidity of samples heated to 44 °C (Fig. 4 A and
B). Reducing the concentration of ALLC significantly reduced the
extent (Fig. 4A) and rate of aggregation (Fig. 4B), demonstrating
that recombinant ALLC aggregates through a concentration-
dependent mechanism.
Because XBP1s and/or ATF6 activation decreases the secretion
of amyloidogenic LC, we reasoned that the stress-independent
activation of these transcriptional programs would similarly de-
crease extracellular ALLC aggregation. Heating the conditioned
media of cells expressing FTALLC to 55 °C for 0–24 h produced
large soluble aggregates that increase with time, as discerned
by blue native polyacrylamide gel electrophoresis (BN-PAGE)
(Fig. S7A) and gel filtration chromatography (Fig. S7B). Reducing
the extracellular concentration of FTALLC in conditioned media
by dilution with media conditioned on GFP-transfected cells
shows that cell-secreted ALLC aggregation is concentration
dependent (Fig. 4C), where a 1:1 [50% (vol/vol)] dilution of
ALLC conditioned media nearly eliminates ALLC aggregates.
We next evaluated whether stress-independent XBP1s and/or
ATF6 activation similarly attenuates ALLC aggregation. We col-
lected conditioned media from FTALLC-expressing HEK293DAX
cells following XBP1s and/or ATF6 activation and measured
ALLC aggregation using BN-PAGE. ATF6 activation resulted in
a 73% loss of soluble FTALLC aggregates (55 °C, 8 h incubation;
Fig. 4 D and E), whereas XBP1s activation resulted in a 20% loss,
and activating both XBP1s and ATF6 reduced aggregate formation
by 60% (Fig. 4 D and E). As expected, the reduction in ALLC
aggregation corresponds with a decrease in total extracellular
ALLC (Fig. 4 D and E). Interestingly, the reduction in ALLC
Fig. 3. Stress-independent activation of XBP1s and/or ATF6 decreases the secretion of amyloidogenic LC. (A) ALLC levels determined by ELISA in conditioned
media from HEK293DAX cells (40) expressing FTALLC following a 15-h preactivation of XBP1s (X; Dox, 1 μg/mL) or ATF6 (A; TMP, 10 μM) or by thapsigargin-
induced stress (Tg, 500 nM). ALLC secretion levels were normalized to vehicle (Vh; DMSO) conditions (n = 3). (B) Representative autoradiogram of [35S]-labeled FTALLC
immunopurified from media and lysates collected from transfected HEK293T-Rex cells following a 15-h preactivation of XBP1s (X; Dox, 1 μg/mL), ATF6
(A; TMP, 10 μM), or both (X/A). The metabolic labeling protocol used is shown. (C) Quantification of fraction secreted from autoradiograms as shown in B
(n ≥ 3). (D) Graph depicting the total [35S]-labeled FTALLC remaining at 4 h in lysate and media following a 15-h preactivation of XBP1s, ATF6, or both in
HEK293DAX (n ≥ 3). (E) Graph depicting the total intracellular [35S]-labeled FTALLC in lysates at 4 h in HEK293DAX cells following a 15-h preactivation of XBP1s,
ATF6, or both (n ≥ 3). The lysate fraction was calculated by dividing the lysate [35S]-labeled FTALLC signal at 4 h by the total [35S]-labeled FTALLC at t = 0. (F)
Immunoblot showing the recovery of the ER chaperones BiP and GRP94 in FLAG immunopurifications from cross-linked HEK293DAX cells expressing FTALLC
following 15-h pretreatment with thapsigargin (Tg), XBP1s (X), ATF6 (A), or XBP1s and ATF6 (X/A), as in B. HEK293DAX cells expressing untagged ALLC is shown
as a control (Ct). (G) Quantification of F achieved by comparing the signal under various conditions to vehicle, and by normalizing to the recovered FTALLC.
*P < 0.05; **P < 0.01; ***P < 0.005. All error bars represent the SEM from biological replicates.
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aggregation was more pronounced than expected from just the
reduction in total extracellular ALLC, suggesting that XBP1s
and/or ATF6 activation could also influence ALLC aggregation
through other mechanisms. Importantly, we do not observe sig-
nificant associations between ALLC and the ER chaperones BiP
and GRP94 in conditioned media, indicating that the reduction in
extracellular ALLC aggregation cannot be attributed to increased
association with these ER chaperones secreted from cells (Fig.
S8A). ALLC secretion and aggregation was not sensitive to
treatment with Dox, TMP, or both in the control HEK293DYG
cells (Fig. S8B), demonstrating that the reduced aggregation of
ALLC observed in HEK293DAX requires XBP1s and/or ATF6
transcriptional activity.
Discussion
We show that stress-independent activation of one or both of the
adaptive UPR-associated transcription factors XBP1s or espe-
cially ATF6 reduces the secretion and extracellular concentra-
tion of amyloidogenic ALLC, reducing soluble ALLC aggregate
levels. This strategy has the potential to be clinically meaningful,
as a >50% reduction in the amount of circulating amyloidogenic
LC mediated by chemotherapeutic methods correlates with
a substantial survival benefit (44). Lowering the amount of
amyloidogenic LC secreted from plasma cells into the blood by
UPR activation should be useful in patients with significant
cardiac and/or renal involvement. This approach, with time,
should dramatically reduce amyloidogenic LC oligomer levels
and thus proteotoxicity, enabling the patient to tolerate estab-
lished chemotherapy regimens. Arm-selective UPR activation could
also be used in combination with chemotherapy approaches to
further reduce the amount of circulating LC and organ proteotox-
icity. Lastly, the approach could potentially be useful in cases of AL
recurrence, decreasing the amyloidogenic LC secretion and organ
proteotoxicity in chemotherapy-resistant AL patients.
Partitioning of amyloidogenic LCs between folding and traf-
ficking vs. degradation pathways is determined by the inter-
actions between the destabilized LC and ER proteostasis
network components. The stoichiometry of the components of
the ER proteostasis network is regulated by the activated sig-
naling arms of the UPR (40). This in turn determines the specific
ER proteostasis factors that interact with amyloidogenic LC and,
thus, dictates the partitioning of LC between retention, secre-
tion, or degradation in the ER lumen. The degradation of
FTALLC upon XBP1s activation accounts for most of the ob-
served reduction in secretion. In contrast, ATF6 activation does
not induce ALLC degradation in HEK293DAX but instead leads
to intracellular retention of ALLC, consistent with the in-
creased interactions between ALLC and the ER chaperones
BiP and GRP94. In AL-patient plasma cells, the retention of
an amyloidogenic LC could sensitize the cells to death by sub-
sequent chemotherapy strategies, or by itself be cytotoxic. Al-
ternatively, degradation could eventually occur with repeated but
periodic ATF6 activation, although this potential mechanism
needs to be further explored. Increasing ER quality control by
arm-selective UPR activation appears to be a general approach
to reduce the secretion of destabilized, aggregation-prone pro-
teins (37). Activation of ATF6 selectively reduces the secretion of
destabilized, amyloidogenic transthyretin mutants from hepa-
tocytes and can reduce intracellular accumulation of mutant
rhodopsin, while not affecting secretion of the wild-type proteins
(40, 41), providing strong support for this hypothesis.
Based on the results described above, we are now seeking small
molecules that activate the ATF6 and/or XBP1s arms of the UPR.
These small molecules would transcriptionally remodel the ER
proteostasis network in plasma cells, reducing the secretion of en-
ergetically destabilized LCs irrespective of their primary structure,
obviating the need for sequence- and conformation-specific AL
drug design challenged by the significant sequence heterogeneity
associated with LC proteotoxicity in AL. Furthermore, based on
other reports demonstrating the capacity of XBP1s and/or ATF6
activation to influence aberrant ER quality control linked to dis-
ease-associated proteotoxicity (40, 41), establishing small molecules
that increase ER quality control is expected to have significant po-
tential for the treatment of additional protein aggregation diseases.
Materials and Methods
Plasmids, Cell Culture, HTS, and Recombinant Protein Production. Detailed
protocols can be found in SI Materials and Methods.
Pulse-Chase Experiments. HEK293DAX or HEK293T-Rex cells plated on poly-D-
lysine coated plates were metabolically labeled in DMEM -Cys/-Met (CellGro)
supplemented with glutamine, penicillin/streptomycin, 10% dialyzed FBS, and
[35S]-Translabel (MP Biomedical) for 30 min. Cells were washed with complete
media and incubated in DMEM for the indicated times and harvested at the
indicated times. In the case of added inhibitors, cells were pretreated for 4 h at
the indicated concentrations, and inhibitors were added to the pulse and chase
media. Lysates were prepared in radioimmunoprecipitation assay buffer plus
protease inhibitor mixture (Roche) with 10 mM CaCl2. Proteins were immuno-
purified using anti-FLAG M1 agarose beads (Sigma). Protein was eluted by
boiling in Laemmli buffer + 100 mM DTT, and samples were separated by SDS-
PAGE. The gels were dried, exposed to phosphorimager plates (GE Healthcare),
Fig. 4. Stress-independent activation of XBP1s and
especially ATF6 reduces aggregation of cell-secreted
ALLC. (A) Timecourses of recombinant ALLC aggre-
gation at the indicated concentrations. Samples
were incubated at 44 °C for the indicated time, and
aggregation was measured by turbidity at 405 nm.
(B) Plot of the t50 of recombinant ALLC aggregation
at the indicated concentration from data as shown
in A; n = 3 replicates are shown. (C) Immunoblots for
BN-PAGE and SDS-PAGE of media conditioned on
HEK293DAX cells expressing FTALLC for 24 h. The
media was diluted with media conditioned on GFP-
expressing cells, as indicated, and incubated at
55 °C for 8 h. (D) Representative immunoblots for
BN-PAGE and SDS-PAGE of media conditioned on
HEK293DAX cells following a 16-h preactivation of
XBP1s (X), ATF6 (A), or XBP1s and ATF6 (X/A), as in
Fig. 3B. FTALLC aggregation was induced by in-
cubating the media for 8 h at 55 °C. (E) Graph
depicting the quantification of soluble aggregates
and total ALLC from BN-PAGE and SDS-PAGE immu-
noblots, as shown in D, normalized to vehicle. Error
bars represent SEM from biological replicates (n = 3).
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and imaged with a Typhoon imager. Band intensities were quantified in
ImageQuant. Fraction secreted was calculated using the equation: fraction se-
creted= [extracellular [35S]-LC signal at t= t/(extracellular [35S]-LC signal at t= 0 +
intracellular [35S]-LC signal at t = 0)]. Fraction remaining was calculated using the
equation: [(extracellular [35S]-LC signal at t = t + intracellular [35S]-LC signal at
t = t)/(extracellular [35S]-LC signal at t = 0 + intracellular [35S]-LC signal at t = 0)].
Conditioned Media Aggregation and Blue Native PAGE. HEK293DAX cells
expressing LC or GFP control were treated with vehicle, doxycycline (Dox),
trimethoprim (TMP), or the combination for 16 h. The medium was removed,
centrifuged at 200 × g to remove cell debris, transferred to a new tube, and
protease inhibitor mixture (Roche) added. The medium was incubated at
55 °C with aliquots removed at the indicated timepoints.
Conditioned medium was added to blue native PAGE loading dye (10%
glycerol, 0.5% Coomassie G-250) and then loaded onto 3–12% Bis-Tris
gradient gels (Invitrogen). The cathode buffer contained 50 mM Tricene and
15 mM Bis-Tris, pH 7.0 with 0.02% Coomassie G-250. The anode buffer
contained 50 mM Bis-Tris pH 7.0. The gels were transferred onto PVDF
membranes, and LC was detected by polyclonal anti-human lambda LC
(Bethyl Laboratories), followed by HRP-conjugated secondary antibodies.
The blots were imaged using a chemiluminescence substrate (Luminata
Forte Western Luminescence Substrate, Millipore) and imaged by film or
with a Bio-Rad scanner.
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